Contents

Current Pharmaceutical Design, Volume 17 - Number 2

Editorial [Hot topic:Novel Potential Therapeutic Approaches for Schizophrenia (Executive Guest Editor: Kenji Hashimoto)]

, 17(2): 92 - 93

Kenji Hashimoto


DOI: 10.2174/1381612811109020092




Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia

, 17(2): 94 - 102

Shigeyuki Chaki and Hirohiko Hikichi


DOI: 10.2174/138161211795049570




Recent Advances in the Discovery of D-Amino Acid Oxidase Inhibitors and Their Therapeutic Utility in Schizophrenia

, 17(2): 103 - 111

Dana V. Ferraris and Takashi Tsukamoto


DOI: 10.2174/138161211795049633




Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia

, 17(2): 112 - 120

Kenji Hashimoto


DOI: 10.2174/138161211795049598




α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia

, 17(2): 121 - 129

Masatomo Ishikawa and Kenji Hashimoto


DOI: 10.2174/138161211795049561




Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects

, 17(2): 130 - 136

Norbert Muller, Aye-Mu Myint and Markus J. Schwarz


DOI: 10.2174/138161211795049552




PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia

, 17(2): 137 - 150

Jan Kehler and Jacob Nielsen


DOI: 10.2174/138161211795049624




Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders

, 17(2): 151 - 167

Silvia Paba, Roberto Frau, Sean C. Godar, Paola Devoto, Francesco Marrosu and Marco Bortolato


DOI: 10.2174/138161211795049589




Role of Polyunsaturated Fatty Acids and Fatty Acid Binding Protein in the Pathogenesis of Schizophrenia

, 17(2): 168 - 175

Motoko Maekawa, Yuji Owada and Takeo Yoshikawa


DOI: 10.2174/138161211795049615




MicroRNAs: A Novel Therapeutic Target for Schizophrenia

, 17(2): 176 - 188

Javier A. Bravo and Timothy G. Dinan


DOI: 10.2174/138161211795049543




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science